Skip to main content

Outcomes

Damage in Childhood Lupus

EurekAlert!

Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise. The EULAR/ACR-2019 criteria have shown sensitivity in cSLE patients, which could allow earlier

Read Article

New Treatments for Systemic Sclerosis

EurekAlert!

Autologous hematopoietic stem cell transplantation (aHSCT) for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. Two abstracts

Read Article

Achieving drug-free remission in axSpA

EurekAlert!

A clinical trial in early axial spondyloarthritis (axSpA) demonstrated sustained inactive disease status in over 60% of patients. In axSpA patients with less than 1 year of disease symptoms, male sex, abstinence from smoking and lower BASDAI score at baseline were associated with higher

Read Article

EULAR 2024 – Day 3 Report

EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite

Read Article
Fascinating - @ndb_org installed an app to measure smartphone usage, and texting less and moving less were associated with more flares. The pseudo-wearable in our pockets?? #EULAR2024 POS0678 @RheumNow https://t.co/ZA0hd3Q10d
David Liew @drdavidliew( View Tweet )

Might Synovial Biopsy Predict Rheumatoid Treatment Responses?

EurekAlert!

Multi-modal analysis of rheumatoid arthritis (RA) synovitis pathotypes enables more accurate choices of first line cDMARDs treatment, suggesting a predictive value to synovial biopsy. 

Read Article

Can we withdraw treatment in post-menopausal osteoporosis?

EurekAlert!

Analysis of French claims data, found over half of women initiating oral bisphosphonates (BP) between 2015 and 2020 discontinued treatment for at least one year, which was associated with a 12% increase in fracture risk. While not recommended, 42.5% of women initiating Dmab discontinued

Read Article

EULAR 2024 - Day 1 Report

Wednesday was Day One at EULAR 2024 in Vienna. While the day was a slow start, the poster halls and auditoriums quickly filled with thousands of rheumatologists, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.

Read Article

AI meets Rheumatology: ChatGPT and patient response optimization

Large language models, such as ChatGPT, are advanced systems trained on vast amounts of text data, far exceeding what a human can read in a lifetime, to understand and generate human-like language. With these tools at our disposal, they are inevitably making their way into healthcare. One

Read Article

Is Cannabis Safe? (6.7.2024)

Dr. Jack Cush reviews FDA approval, news and journal articles -- and it’s the week before EULAR 2024 in Vienna!!

Read Article

Cannabis Use is Common, But is it Safe?

Two current JAMA reports suggest that cannabis use is not only common, but that if heavily used may increase mortality rates.

Read Article

Molecular Profile for Cardiovascular Risk in Rheumatoid Arthritis

A new study led by the University of Córdoba, the Maimonides Institute for Biomedical Research and the Rheumatology Department at the Reina Sofía University Hospital in Córdoba has managed to establish, for the first time, the molecular profile of those patients with rheumatoid arthritis who

Read Article

JAK or TNF Inhibitor as First Drug for Rheumatoid Arthritis?

Medpage Today

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs had failed, a pragmatic head-to-head trial found.

Read Article

Role of Diet in Gout Risk

Diet has long been influential in gout care and risks. A large cohort study has shown that plant-based diets may reduce the risk of developing gout.

This prospective study assessed the risk of developing incident gout based on consumption of healthy and unhealthy plant-based diets.

Read Article

ACR’s Run at Goliath (PCPs) (5.31.2024)

Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?

Read Article

Metformin Lowers Gout Risk in Pre-Diabetes

A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout. 

Metformin is widely used for diabetes and pre-diabetes. Importantly, its use has been linked with a

Read Article

Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis

A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO. 

Read Article

Hypertension not associated with High NSAID Doses in AxSpA

Medscape

At the recent SPARTAN annual meeting in Cleveland, Dr. Jose Meade-Aguilar reported that amongst axial spondyloarthritis patients receiving nonsteroidal anti-inflammatory drugs, there was no difference in the risk for hypertension when comparing those on high vs. low dose NSAIDs.

Read Article

Biomarkers Predictive of a Deucravacitinib Response in Psoriatic Arthritis

A phase II trial demonstrating the clinical efficacy of deucravacitinib, a TYK2 inhibitor, in psoriatic arthritis (PsA) suggests specific biologic effects identified by biomarkers may predict clinical responses.

Read Article

Window of Opportunity in Psoriatic Arthritis

The Dutch southwest Early psoriatic arthritis (PsA) cohort study has demonstrated that the earlier the referral and diagnosis of PsA, the better the outcome. 

Read Article

No Link Between Autoimmune Diseases and Monoclonal Gammopathy of Undetermined Significance

Annals of Internal Medicine reports a study of more than 75,000 persons screened for monoclonal gammopathy of undetermined significance (MGUS) and found no association between autoimmune rheumatic disease (AIRD) and MGUS.

While MGUS may be a precursor to

Read Article

SLE Cost of Care and Disease Activity

A longitudinal, multinational study shows that SLE patients achieving remission or low disease activity incur lower overall direct/indirect (DCs, ICs) healthcare costs than those with persistent activity. 

The study included

Read Article

Upside/Downside of Steroids in Lupus Nephritis

A systematic review of randomized clinical trials of patients with biopsy-proven lupus nephritis (LN) demonstrates both the benefits and harms to early glucocorticoid (GC) regimens on lupus outcomes. 

This meta-analysis of the control arms of 50 RCTs

Read Article

"Don't You Know Who I am?" (5.17.2024)

Dr. Jack Cush reviews the news and journal reports from the past 2 weeks. This week's question: can we prevent gout, ILD or psoriasis?

Read Article

Infectious Mortality in Autoimmune Rheumatic Disorders

Infectious conditions are a significant cause of mortality in autoimmune rheumatic diseases (ARD). Among patients hospitalized with an infection, we compared in-hospital and long-term (3-year) mortality between those with and without ARD.

Read Article